# Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

Source: https://onco.cc/trials/nct06593431/  
OnCo record `nct06593431` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in pancreatic cancer, run by M.D. Anderson Cancer Center, now recruiting.

## Summary

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial is a phase 3, randomised interventional study registered as NCT06593431 by M.D. Anderson Cancer Center, with a registry enrolment figure of 80 participants, started 2024-10-23 and due to reach its primary completion in 2029-06-29. Interventions recorded: Consolidative Radiation. Conditions listed: Pancreas Cancer; Oligometastatic. Primary outcome: Safety and Adverse Events (AEs). Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic ductal adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06593431
- Phase: 3
- Setting: Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06593431: https://clinicaltrials.gov/study/NCT06593431

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06593431.json